论文部分内容阅读
近日,美国生物技术公司Prothena宣布,与罗氏(Roche)合作研发的针对帕金森病的单抗药物PRX002将进入Ⅱ期临床试验。PRX002正是针对α-synuclein的单抗药物,它可阻止非正常折叠的α-synuclein蛋白在大脑中传播,并将其清除出大脑,有望从根本上解决帕金森病。据了解,Prothena已经完成了PRX002在帕金森病患者中的Ⅰb期临床试验。试验发现,PRX002能够迅速进入患者脑部,并减少α-synuclein,尤其是聚积的α-synuclein蛋白水平,患者血清中α-synuclein浓度下降多达97%。同时,这个药
Recently, the U.S. biotechnology company Prothena announced that PRX002, a monoclonal antibody against Parkinson’s disease developed in cooperation with Roche, will enter phase II clinical trials. PRX002 is a monoclonal antibody against α-synuclein, which prevents the abnormally folded α-synuclein from spreading in the brain and clears it out of the brain, promising to fundamentally solve Parkinson’s disease. It is understood that Prothena has completed the phase Ⅰ b clinical trial of PRX002 in patients with Parkinson’s disease. The trial found that PRX002 can rapidly enter the brain of patients and reduce the level of α-synuclein, especially the accumulation of α-synuclein, with a decrease of as much as 97% in the serum of patients. At the same time, this medicine